Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 440Lung Neoplasms 170Neoplasms 31Adenocarcinoma of Lung 27Neoplasm Metastasis 23Breast Neoplasms 23Prostatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Small Cell Lung Carcinoma 17Colorectal Neoplasms 13Melanoma 12Stomach Neoplasms 11Adenocarcinoma, Bronchiolo-Alveolar 11Pancreatic Neoplasms 10Ovarian Neoplasms 10Carcinoma, Renal Cell 10Head and Neck Neoplasms 9Urinary Bladder Neoplasms 8Recurrence 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Squamous Cell 8Salivary Gland Neoplasms 7Esophageal Neoplasms 7NSCLC 6Carcinoma 6Advanced Non-Small Cell Lung Cancer 6Sarcoma 5Pleural Effusion, Malignant 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Transitional Cell 5

Interventions

Docetaxel 4pembrolizumab 3Pemetrexed 3Nivolumab 2Cisplatin 2Carboplatin 2tislelizumab 1rofecoxib 1paclitaxel poliglumex 1osimertinib 1nazartinib 1lenvatinib 1cemiplimab 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Radiosurgery 1RO5126766 1Platinum Compounds 1Midazolam 1Gemcitabine 1Gefitinib 1Food 1Esomeprazole 1Drug Therapy 1Dabigatran 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × Docetaxel × Thoracic × Clear all
NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05215067 2025-03-12

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Akeso

Phase 2 Active not recruiting
44 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06775483 2025-01-15

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Not yet recruiting
220 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡